Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001267065 | SCV001445246 | pathogenic | Inborn genetic diseases | 2018-02-26 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001880131 | SCV002190564 | pathogenic | Cohen syndrome | 2020-12-25 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Val3911Serfs*31) in the VPS13B gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 112 amino acid(s) of the VPS13B protein. For these reasons, this variant has been classified as Pathogenic. This variant disrupts the C-terminus of the VPS13B protein. Other variant(s) that disrupt this region (p.Pro3969Leufs*41) have been determined to be pathogenic (PMID: 15141358, Invitae). This suggests that variants that disrupt this region of the protein are likely to be causative of disease. This variant has not been reported in the literature in individuals with VPS13B-related conditions. ClinVar contains an entry for this variant (Variation ID: 985909). This variant is not present in population databases (ExAC no frequency). |